Cinacalcet is a calcimimetic that decreases PTH, specifically demonstrated in a phase 3 study in patients with primary hyperparathyroidism [104], and increases phosphate reabsorption, which has demonstrated some benefits. The gene discussed is PTH; the disease is primary hyperparathyroidism.